The balance between proliferation and apoptosis is represented by changes in the expression of the tissue markers, Bcl-2 and p53, and the presence of silver-stained nucleolar organizing regions (AgNOR) on DNA in prostate adenocarcinomas. Identifying a mathematical model that would take into account the opposing nature of both processes and relate this to cancer stage and grade would be a useful adjunct for studying disease behaviour. This retrospective study investigated tissue marker expression in prostate adenocarcinoma biopsy samples from 17 patients. Staining for p53 was inversely correlated with patient age. Staining for Bcl-2 correlated with the presence of advanced metastatic cancer and American Joint Committee on Cancer (AJCC) disease stage. A mathematical model was developed which combined coded staining intensity data for Bcl-2 and AgNOR, as markers of proliferation, and for p53, as a marker of apoptotis. The mathematical model significantly correlated with Gleason score, AJCC stage and serum prostate specific antigen level, whereas each tissue marker alone did not correlate with all these measures.
ŽakeljM Primic: Cancer Incidence in Slovenia 2006. Ljubljana: Institute of Oncology, 2007 [in Slovenian].
2.
GarciaMJemalAWardEM: Global Cancer Facts & Figures 2007. Atlanta: American Cancer Society, 2007.
3.
EpsteinJIPartinAWSauvageotJ: Prediction of progression following radical prostatectomy. A multivariate analysis of 721 men with long-term follow-up. Am J Surg Pathol1996; 20: 286–292.
4.
GotoTNguyenBPNakanoM: Utility of Bcl-2, P53, Ki-67, and caveolin-1 immunostaining in the prediction of biochemical failure after radical prostatectomy in a Japanese population. Urology2008; 72: 167–171.
5.
JhaveriFZippeCDKleinEA: Biochemical failure does not predict overall survival after radical prostatectomy for localized prostate cancer: 10-year results. Urology1999; 54: 884–890.
6.
VergisRCorbishleyCMNormanAR: Intrinsic markers of tumor hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: A retrospective analysis of two randomised radiotherapy trials and one surgical cohort study. Lancet Oncol2008; 9: 342–351.
7.
KehindeEOMaghrebiMAAnimJT: The importance of determining the aggressiveness of prostate cancer using serum and tissue molecular markers. Can J Urol2008; 15: 3967–3974.
8.
OxleyJDWinklerMHParryK: p53 and bcl-2 immunohistochemistry in preoperative biopsies as predictors of biochemical recurrence after radical prostatectomy. BJU Int2002; 89: 27–32.
9.
AlbertsBJohnsonAWalterP (eds): Molecular Biology of the Cell, 5th edn.New York: Garland Publishing, 2008; p 1217.
10.
ThomasNSBLatchmanDS (eds): Apoptosis and Cell Cycle Control in Cancer, 1st edn.Oxford: Bios Scientific Publishers, 1996; pp 59–63.
11.
ThomasNSBLatchmanDS (eds): Apoptosis and Cell Cycle Control in Cancer, 1st edn.Oxford: Bios Scientific Publishers, 1996; pp 116–118.
12.
AlbertsBJohnsonAWalterP (eds): Molecular Biology of the Cell, 5th edn.New York: Garland Publishing, 2008; p 1001.
13.
MiyakeHMuramakiMKurahashiT: Expression of potential molecular markers in prostate cancer: Correlation with clinicopathological outcomes in patients undergoing radical prostatectomy. Urol Oncol2008; doi: 10.1016/j.urolonc.2008.08.001.
14.
Van der PoelHG: Molecular markers in the diagnosis of prostate cancer. Crit Rev Oncol Hematol2007; 61: 104–139.
15.
ThomasNSBLatchmanDS (eds): Apoptosis and Cell Cycle Control in Cancer, 1st edn.Oxford: Bios Scientific Publishers, 1996; pp 118–120.
16.
ThomasNSBLatchmanDS (eds): Apoptosis and Cell Cycle Control in Cancer, 1st edn.Oxford: Bios Scientific Publishers, 1996; p 140.
17.
GodefroyNBouleauSGruelG: Transcriptional repression by p53 promotes a Bcl-2-insensitive and mitochondria-independent pathway of apoptosis. Nucleic Acids Res2004; 32: 4480–4490.
18.
GregoryG: Apoptosis and the Immune Response (ChristopherDG, ed). New York: Wiley-Liss, 1995; pp 383–386.
19.
ConcatoJJainDLiWW: Molecular markers and mortality in prostate cancer. BJU Int2007; 100: 1259–1263.
20.
DerenziniMPessionATrereD: Quantity of nucleolar silver-stained proteins is related to proliferating activity in cancer cells. Lab Invest1990; 63: 137–140.
21.
LeekRDAlisonMRSarrafCE: Variations in the occurrence of silver-staining nucleolar organizer regions (AgNORs) in non-proliferating and proliferating tissues. J Pathol1991; 165: 43–51.
22.
CrockerJNarP: Nucleolar organizer regions in lymphomas. J Pathol1987; 151: 111–118.
23.
GambiniCSementaARBorgianiL: Quantitative evaluation of the nucleolus organizer regions (NORs) in malignant melanoma of the skin: Is it a new prognosis index?Pathologica1989; 81: 239–249 [in Italian].
24.
BauerJJSesterhennIAMostofiFK: Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer. J Urol1996; 156: 1511–1516.
25.
AgrawalSDunsmuirWD: Molecular markers in prostate cancer. Part I: Predicting lethality. Asian J Androl2009; 11: 14–21.
26.
ChinJLReiterRE: Molecular markers and prostate cancer prognosis. Clin Prostate Cancer2004; 3: 157–164.
MoulJW: Angiogenesis, p53, bcl-2 and Ki-67 in the progression of prostate cancer after radical prostatectomy. Eur Urol1999; 35: 399–407.
29.
GreeneFLPageDLFlemingID: AJCC Cancer Staging Manual, 6th edn.New York: Springer, 2002.
30.
PlotonDMenagerMJeannessonP: Improvement in the staining and in the visualization of the argyrophilic proteins of the nucleolar organizer region at the optical level. Histochem J1986; 18: 5–14.
UlmertDO'BrienMFBjartellAS: Prostate kallikrein markers in diagnosis, risk stratification and prognosis. Nat Rev Urol2009; 6: 384–391.
33.
QuinnDIHenshallSMHeadDR: Prognostic significance of p53 nuclear accumulation in localized prostate cancer treated with radical prostatectomy. Cancer Res2000; 60: 1585–1594.
34.
LeibovichBCChengLWeaverAL: Outcome prediction with p53 immunostaining after radical prostatectomy in patients with locally advanced prostate cancer. J Urol2000; 163: 1756–1760.
35.
RakozyCGrignonDJLiY: p53 gene alterations in prostate cancer after radiation failure and their association with clinical outcome: A molecular and immunohistochemical analysis. Pathol Res Pract1999; 195: 129–135.
36.
StackhouseGBSesterhennIABauerJJ: p53 and bcl-2 immunohistochemistry in pretreatment prostate needle biopsies to predict recurrence of prostate cancer after radical prostatectomy. J Urol1999; 162: 2040–2045.
37.
DhirRVietmeierBArlottiJ: Early identification of individuals with prostate cancer in negative biopsies. J Urol2004; 171: 1419–1423.
38.
SakrWASarkarFHSreepathiP: Measurement of cellular proliferation in human prostate by AgNOR, PCNA, and SPF. Prostate1993; 22: 147–154.
39.
BarresiVCerasoliSVitarelliE: Density of microvessels positive for CD105 (endoglin) is related to prognosis in meningiomas. Acta Neuropathol2007; 114: 147–156.
40.
SatohTYangGEgawaS: Caveolin-1 expression is a predictor of recurrence-free survival in pT2N0 prostate carcinoma diagnosed in Japanese patients. Cancer2003; 97: 1225–1233.
